Eli Lilly and Company announced a $2.75 billion partnership with Insilico Medicine, an artificial intelligence-powered drug discovery company, to develop and commercialize new pharmaceutical treatments using AI technology.

The collaboration represents one of the largest deals between a major pharmaceutical company and an AI drug discovery firm. Under the agreement, Insilico Medicine will leverage its artificial intelligence platforms to identify and develop potential drug candidates, while Eli Lilly will provide funding and handle clinical development and global commercialization.

Insilico Medicine specializes in using machine learning algorithms and AI to accelerate the traditionally lengthy and expensive drug discovery process. The company's platforms analyze biological data to identify novel drug targets and design potential therapeutic compounds more rapidly than conventional methods.

The partnership reflects the pharmaceutical industry's growing investment in artificial intelligence technologies to streamline drug development. Traditional drug discovery can take over a decade and cost billions of dollars, with high failure rates in clinical trials. AI-powered approaches promise to reduce both timelines and costs while improving success rates.

Eli Lilly, based in Indianapolis, has been actively expanding its technology partnerships as part of its strategy to maintain a robust pipeline of new treatments. The company manufactures drugs for diabetes, cancer, and other conditions, and has been seeking innovative approaches to drug development to maintain its competitive position in the global pharmaceutical market.